LETTER FROM PROFESSOR ROBERT KYLE
X International Conference: Complex Treatment of Plasma Cell Dyscrasias in 2022
This up-to-date and important 1-day conference has been organized by Professor Artur Jurczyszyn of the Jagiellonian University Medical College in Krakow, Poland.
There will be a Welcome Dinner on Friday, September 16, 2022, at 5:00 p.m.
Artur Jurczyszyn will open the sessions at 12:30 p.m. on Saturday, September 17, 2022.
The chairmen of Session I consist of Professors Piotr Rzepecki, Andrzej Deptala, Lidia Usnarska-Zubkiewicz and Jan Maciej Zaucha.
The first speaker is Professor David H. Vesole, John Theurer Cancer Center, Hackensak University Medical Center, New Jersey, USA, on “Multiple Myeloma – Update on the Clinical Use of MRD”. Dr. Vesole has had an extensive experience with the diagnostic and management aspects of multiple myeloma and a leader in the field for decades.
Professor Rafael Fonseca, Mayo Clinic, Arizona, USA, will follow with a presentation on “Personalized Treatment for Myeloma – The Story of Venetoclax”. Professor Fonseca began his outstanding career at Mayo Clinic Rochester and subsequently transferred to Mayo Clinic Arizona, USA. He and his colleagues have made many important advances utilizing cytogenetics for the past two decades.
Professor Kwee Yong, University College Hospital, London, United Kingdom, will present an important address entitled “Does Every Transplant Eligible Newly Diagnosed Patient Need an Autologous Stem Cell Transplant in 2022?” This is an important decision for every eligible stem cell transplant patient at the present time. Not all clinicians are convinced that an autologous transplant is indicated for every eligible patient. We will hear the pros and cons of autologous stem cell transplantation at the current time.
Professor Jean-Luc Harousseau, Centre René Gauducheau, Insitut de l’Ouest, Nantes-St. Herblain, France. Professor Harousseau is a long-time investigator and leader in France, the remainder of Europe, as well as the world. He will present on “Post Autologous Transplantation Strategies in Newly Diagnosed Multiple Myeloma”.
Following the coffee break, the chairmen of Session II are Professors Jerzy Hołowiecki, Wiesław W. Jędrzejczak, Sebastian Grosicki and Bogusław Machaliński.
The first presentation of Session II is Professor Irit Avivi, Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, who will speak on “Prognostic and Clinical Significance of Immune Recovery Post Therapy in Multiple Myeloma.”
This will be followed by a presentation by Professor Joshua Richter, Myeloma Division, Tisch Cancer Institute, Icahn School of Medicine, at Mount Sinai Hospital, New York, USA. He will address “Amyloidosis and POEMS – how I treat them in 2022” which are important plasma cell disorders with an emphasis on therapy at the present time.
Session II will be continued by Professor Joan Blade, Amyloidosis and Myeloma Unit Hospital Clinic de Barcelona, Spain, who will speak on Monoclonal Gammopathy of Clinical Significance – practical aspects.
Professor Chaim Shustik, McGill University, Faculty of Medicine, Montreal, Canada, who will tell us about the Treatment of Multiple Myeloma in Canada at the present time. Dr. Shustik has been a leader in the myeloma community of Montreal as well as the remainder of Canada.
Professor Carlos Fernandez de Larrea, Amyloidosis and Myeloma Unit Hospital Clinic de Barcelona, Spain, will address an important therapeutic approach with his presentation “CAR-T Cell Therapy for Multiple Myeloma”.
This will be followed by Professor Guillermo J. Ruiz-Arguelles, Centro de Hematologia y Medicina Interna de Puebla, Clinica Ruiz, Puebla, Mexico, who will tell the attendees about “Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings”.
The afternoon session will close with a presentation on “Plasma Cell Leukemia – What is New in 2022” by the host, Professor Artur Jurczyszyn.
The sessions will be followed by a dinner at La Grande Mamma at 6:30 p.m.
This conference will update the attendees on the clinical use of MRD for multiple myeloma, personalized treatment for myeloma – the story of venetoclax, post-autologous transplantation strategies in newly diagnosed multiple myeloma, prognostic and clinical significance of immune recovery post therapy in multiple myeloma, amyloidosis and POEMS treatment in 2022, Monoclonal Gammopathy of Clinical Significance – practical aspects, as well as an update in treatment of multiple myeloma in Canada. The role of CAR-T cell therapy is emphasized, lessons learned treating patients with multiple myeloma in resource-constrained settings and plasma cell leukemia – what is new in 2022 by international experts.
Professor of Medicine
Laboratory Medicine & Pathology